<DOC>
	<DOCNO>NCT00074698</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability FG-3019 , therapeutic antibody design block pro-fibrotic activity connective tissue growth factor ( CTGF ) . CTGF trigger production collagen fibronectin , cause scar thicken lung . Approximately 18 27 male female , 21 80 year age diagnosis idiopathic pulmonary fibrosis ( IPF ) enrol study . The duration study approximately one month , patient receive single infusion FG-3019 . In addition , two follow-up visit 6 12 month receive study drug .</brief_summary>
	<brief_title>Safety Tolerability Study FG-3019 Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>21 80 year age diagnosis IPF surgical lung biopsy accord American Thoracic Society criterion history significant exposure organic inorganic dust drug know cause IPF interstitial lung disease IPF pulmonary fibrosis associate connective tissue disease form idiopathic interstitial pneumonia , desquamative interstitial pneumonia , acute interstitial pneumonia , nonspecific interstitial pneumonia , cryptogenic organize pneumonia endstage IPF ( total lung capacity le 45 % predict value ) list lung transplantation time study enrollment significant heart problem pregnant lactating ( female )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Pulmonary fibrosis</keyword>
	<keyword>Respiratory disease</keyword>
</DOC>